Spyre Therapeutics (SYRE) Payables (2016 - 2025)
Spyre Therapeutics' Payables history spans 11 years, with the latest figure at $14000.0 for Q4 2025.
- For Q4 2025, Payables fell 97.9% year-over-year to $14000.0; the TTM value through Dec 2025 reached $14000.0, down 97.9%, while the annual FY2025 figure was $14000.0, 97.9% down from the prior year.
- Payables reached $14000.0 in Q4 2025 per SYRE's latest filing, down from $7.5 million in the prior quarter.
- In the past five years, Payables ranged from a high of $19.8 million in Q3 2023 to a low of $14000.0 in Q4 2025.
- Average Payables over 5 years is $4.8 million, with a median of $2.7 million recorded in 2023.
- Peak YoY movement for Payables: soared 2349.63% in 2023, then crashed 99.04% in 2025.
- A 5-year view of Payables shows it stood at $3.3 million in 2021, then crashed by 79.6% to $677000.0 in 2022, then skyrocketed by 2349.63% to $16.6 million in 2023, then plummeted by 95.98% to $666000.0 in 2024, then tumbled by 97.9% to $14000.0 in 2025.
- Per Business Quant, the three most recent readings for SYRE's Payables are $14000.0 (Q4 2025), $7.5 million (Q3 2025), and $31000.0 (Q2 2025).